tixagevimab   Click here for help

GtoPdb Ligand ID: 11330

Synonyms: AZD8895 | COV2-2196 | Evusheld® (tixagevimab + cilgavimab)
Approved drug
tixagevimab is an approved drug (EMA (2022))
Compound class: Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (EMA (2022))
International Nonproprietary Names Click here for help
INN number INN
11776 tixagevimab
Synonyms Click here for help
AZD8895 | COV2-2196 | Evusheld® (tixagevimab + cilgavimab)
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1111
Other databases
GtoPdb PubChem SID 434321765
Search PubMed clinical trials tixagevimab
Search PubMed titles tixagevimab
Search PubMed titles/abstracts tixagevimab